Literature DB >> 16861547

Risk-benefit analysis of X-ray exposure associated with lung cancer screening in the Italung-CT trial.

Mario Mascalchi1, Giacomo Belli, Marco Zappa, Giulia Picozzi, Massimo Falchini, Riccardo Della Nave, Germana Allescia, Andrea Masi, Andrea Lopes Pegna, Natale Villari, Eugenio Paci.   

Abstract

OBJECTIVE: Prior analyses of X-ray exposures in lung cancer screening with CT considered the basic acquisition technique in single-detector scanners and the effects of a lifetime screening regimen, whereas the potential benefit in terms of lives saved was not addressed.
MATERIALS AND METHODS: We determined the total-body effective dose of different acquisition techniques for one single-detector and one MDCT scanner and made projections about the cumulative radiation exposure to smokers undergoing four annual CT examinations on the same scanners in the Italung-CT Trial. Combining these data with estimates of radiation-induced fatal cancer and of the benefit of screening, we calculated the risk-benefit ratio for participants in the trial, ex-smokers, and never-smokers.
RESULTS: The cumulative effective doses per 1,000 subjects were 3.3 Sv using an MDCT scanner and 5.8 or 7.1 Sv using a single-detector scanner. Potential fatal cancers associated with radiation exposure were 0.11 per 1,000 subjects for MDCT scanners and 0.20 or 0.24 for single-detector scanners, which is about 10-100 times lower than the number of expected lives saved by screening assuming a 20-30% lung cancer-specific mortality reduction in current smokers. They were, however, of similar magnitude to the lives saved by screening in never-smokers and former smokers assuming a 10% efficacy of screening.
CONCLUSION: MDCT is associated with lower radiation doses than single-detector CT technology. The risk of radiation dose in the Italung-CT Trial is compensated for by the expected benefit. CT screening for lung cancer should not be offered to never-smokers, whereas its recommendation in former smokers is debatable.

Entities:  

Mesh:

Year:  2006        PMID: 16861547     DOI: 10.2214/AJR.05.0088

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  15 in total

1.  Dose exposure in the ITALUNG trial of lung cancer screening with low-dose CT.

Authors:  M Mascalchi; L N Mazzoni; M Falchini; G Belli; G Picozzi; V Merlini; A Vella; S Diciotti; F Falaschi; A Lopes Pegna; E Paci
Journal:  Br J Radiol       Date:  2011-10-05       Impact factor: 3.039

Review 2.  Screening for lung cancer using low-dose spiral CT: 10 years later, state of the art.

Authors:  M Zompatori; M Mascalchi; F Ciccarese; N Sverzellati; U Pastorino
Journal:  Radiol Med       Date:  2012-06-28       Impact factor: 3.469

Review 3.  Screening for lung cancer with low-dose computed tomography: a review of current status.

Authors:  Henry M Marshall; Rayleen V Bowman; Ian A Yang; Kwun M Fong; Christine D Berg
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

4.  Lung cancer screening with ultra-low dose CT using full iterative reconstruction.

Authors:  Masayo Fujita; Toru Higaki; Yoshikazu Awaya; Toshio Nakanishi; Yuko Nakamura; Fuminari Tatsugami; Yasutaka Baba; Makoto Iida; Kazuo Awai
Journal:  Jpn J Radiol       Date:  2017-02-14       Impact factor: 2.374

5.  Lung cancer screening with low dose CT and radiation harm-from prediction models to cancer incidence data.

Authors:  Mario Mascalchi; Lapo Sali
Journal:  Ann Transl Med       Date:  2017-09

Review 6.  Lung densitometry: why, how and when.

Authors:  Mario Mascalchi; Gianna Camiciottoli; Stefano Diciotti
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

7.  MicroRNA-145 as ideal biomarker for the diagnosis of various carcinomas.

Authors:  Yanmei Hou; Xiang Wang; Yan Chen; Shengqun Mu
Journal:  Tumour Biol       Date:  2014-12-05

8.  Detection of lung cancer using weighted digital analysis of breath biomarkers.

Authors:  Michael Phillips; Nasser Altorki; John H M Austin; Robert B Cameron; Renee N Cataneo; Robert Kloss; Roger A Maxfield; Muhammad I Munawar; Harvey I Pass; Asif Rashid; William N Rom; Peter Schmitt; James Wai
Journal:  Clin Chim Acta       Date:  2008-03-03       Impact factor: 3.786

Review 9.  Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Douglas E Wood; Ella A Kazerooni; Scott L Baum; George A Eapen; David S Ettinger; Lifang Hou; David M Jackman; Donald Klippenstein; Rohit Kumar; Rudy P Lackner; Lorriana E Leard; Inga T Lennes; Ann N C Leung; Samir S Makani; Pierre P Massion; Peter Mazzone; Robert E Merritt; Bryan F Meyers; David E Midthun; Sudhakar Pipavath; Christie Pratt; Chakravarthy Reddy; Mary E Reid; Arnold J Rotter; Peter B Sachs; Matthew B Schabath; Mark L Schiebler; Betty C Tong; William D Travis; Benjamin Wei; Stephen C Yang; Kristina M Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2018-04       Impact factor: 11.908

Review 10.  Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Anthony J Alberg; Malcolm V Brock; Jean G Ford; Jonathan M Samet; Simon D Spivack
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.